NBRV - Arbutus Biopharma appoints Karen Sims as chief medical officer
2023-07-11 03:46:29 ET
- Arbutus Biopharma ( NASDAQ: ABUS ) has promoted Karen Sims as Chief Medical Officer and named Christopher Naftzger as General Counsel and Chief Compliance Officer, effective immediately..
- Naftzger succeeds Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations.
- Most recently, Karen Sims served as as Vice President, Clinical Development, before being promoted to Chief Medical Officer.
- Most recently Naftzger served as Interim-CEO, General Counsel and Corporate Secretary of Nabriva Therapeutics ( NBRV ).
- The Arbutus board granted Naftzger an option to buy a total of 500,000 common shares in connection with his employment. The option, which is subject to the grant's terms, has an exercise price equal to the stock's closing price on July 10, 2023. It will vest over a four-year period, with 25% of the shares becoming his upon the first anniversary and the remaining 75% becoming his over the following three years.
For further details see:
Arbutus Biopharma appoints Karen Sims as chief medical officer